Biomarkers for the development of antidepressant and anxiolytic drugs

Biomarkers for Psychiatric Disorders

Volumn , Issue , 2009, Pages 427-443

  Ising, Marcus ^a   Holsboer, Florian ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900052173     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-79251-4_17     Document Type: Chapter

References (91)

1. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatr 48: 157-162
2. Ansseau M, von Freckell R, Maassen D, Cerfontaine JL, Papart P, Timsit-Berthier M, Legros JJ, Franck G (1988) Prediction of treatment response to selective antidepressants from clonidine and apomorphine neuroendocrine challenges. In: Briley M, Fillion G (eds) New concepts in depression. McMillan, London, pp 269-276
3. Appelhof BC, Huyser J, Verweij M, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Tijssen JG, Wiersinga WM, Schene AH (2006) Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol Psychiatr 59: 696-701
4. Arana GWB, Ornsteen M (1985) The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatr 42: 1193-1204
5. Aubry JM, Gervasoni N, Osiek C, Perret G, Rossier MF, Bertschy G, Bondolfi G (2007) The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res 41: 290-294
6. Bares M, Brunovsky M, K opecek M, Stopkova P, N ovak T, K ozeny J, H oschl C (2007) Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: A pilot study. J Psychiatr Res 41: 319-325
7. Bauer M, Heinz A, Whybrow PC (2002) Thyroid hormones, serotonin and mood: Of synergy and significance in the adult brain. Mol Psychiatr 7: 140-156
8. Bertolote JM, Fleischmann S (2002) Suicide and psychiatric diagnosis: A world-wide perspective. World Psychiatr 1: 181-186
9. Bijl RV, Ravelli A, van Zessen G (1998) Prevalence of psychiatric disorder in the general population: Results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 33: 587-595
10. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95
11. Brambilla F, Scarone S, Massironi R, Nobile P, P ugnetti L (1982) Abnormal anterior pituitary responsiveness to hypothalamic hormones in primary affective disorders. Effect of desipramine therapy. Neuropsychobiology 8: 269-275
12. Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L (1995) Alpha 2-Adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology 20: 1-9
13. Bruder GE (1992) P300 findings for depressive and anxiety disorders. Ann NY Acad Sci 658: 205-222
14. Carroll BJ, Feinberg M, Greden JF (1981) A specific laboratory test for the diagnosis of melancholia. Arch Gen Psychiatr 38: 15-22
15. Chrousos GP, Schuermeyer TH, Doppman J, Oldfield EH, Schulte HM, Gold PW, Loriaux DL (1985) NIH conference. Clinical applications of corticotropin- releasing factor. Ann Intern Med 102: 344-358
16. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, Rosenberg S, Uijtdehaage SH (2002) Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27: 120-131
17. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M (2005) Changes in prefrontal activity characterize clinical response in SSRI nonresponders: A pilot study. J Psychiatr Res 39: 461-466
18. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, Liebowitz MR, Gorman JM (1995) Persistence of blunted human growth hormone response to clonidine in fluoxetinetreated patients with panic disorder. Am J Psychiatr 152: 619-622
19. Corrigan MH, Gillette GM, Quade D, Garbutt JC (1992) Panic, suicide, and agitation: Independent correlates of the TSH response to TRH in depression. Biol Psychiatr 31: 984-992
20. de Kloet ER, Joels M, Holsboer F (2005) Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6: 463-475
21. De Souza DM, Dias-Neto E (2008) RNA biomarkers in schizophrenia. In: Turck CW (ed) Biomarkers for psychiatric disorders. Springer, Berlin Heidelberg New York
22. Deuschle M, Schmider J, Weber B, Standhardt H, Korner A, Lammers CH, Schweiger U, Hartmann A, Heuser I (1997) Pulse-dosing and conventional application of doxepin: Effects on psychopathology and hypothalamus-pituitary- Adrenal (HPA) system. J Clin Psychopharmacol 17: 156-160
23. Deuschle M, Schweiger U, Gotthardt U, Weber B, Korner A, Schmider J, Standhardt H, Lammers CH, Krumm B, Heuser IJ (1998) The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary- Adrenocortical system than the dexamethasone suppression test. Biol Psychiatr 43: 762-766
24. Ditzen C, Jastorff AM, Kessler MS, Bunck M, Teplytska L, Erhardt A, Kromer SA, Varadarajulu J, Targosz BS, Sayan-Ayata EF, Holsboer F, Landgraf R, Turck CW (2006) Protein biomarkers in a mouse model of extremes in trait anxiety. Mol Cell Proteomics 5: 1914-1920
25. Duval F, Mokrani MC, Crocq MA, Jautz M, Bailey P, Diep TS, Macher JP (1996) Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatr 53: 833-840
26. Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S, Putz B, Uhr M, Binder EB, Holsboer F, Keck ME (2006) Regulation of the hypothalamic-pituitary- Adrenocortical system in patients with panic disorder. Neuropsychopharmacology 31: 2515-2522
27. Frieboes RM, Sonntag A, Yassouridis A, Eap CB, Baumann P, Steiger A (2003) Clinical outcome after trimipramine in patients with delusional depression-A pilot study. Pharmacopsychiatry 36: 12-17
28. Fujimoto M, Uchida S, Watanuki T, Wakabayashi Y, Otsuki K, Matsubara T, Suetsugi M, Funato H, Watanabe Y (2008) Reduced expression of glyoxalase-1 mRNS in mood disorder patients. Neurosci Lett 438:196-199
29. Gold PW, Chrousos GP (1985) Clinical studies with corticotropin releasing factor: Implications for the diagnosis and pathophysiology of depression, Cushing's disease, and adrenal insufficiency. Psychoneuroendocrinology 10: 401-419
30. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, Schulte H, Oldfield E, Loriaux DL (1984) Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatr 141: 619-627
31. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W (1986) Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. New Engl J Med 314: 1329-1335
32. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatr 161: 1256-1263
33. Herr AS, Tsolakidou AF, Yassouridis A, Holsboer F, Rein T (2003) Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology 78: 12-22
34. Heuser IJ, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356
35. Heuser IJ, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Y assouridis A, H olsboer F (1996) Pituitary-Adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatr 153: 93-99
36. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501
37. Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9:638-646
38. Holsboer F, Liebl R, Hofschuster E (1982) Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 4: 93-101
39. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Müller OA (1984) Blunted corticotropin and normal cortisol response to human corticotropin- releasing factor in depression. N Engl J Med 311: 1127
40. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Müller OA, Stalla GK (1986) Human corticotropin-releasing hormone in depression- correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol Psychiatr 21: 601-611
41. Holsboer F, Philipp M, Steiger A, Gerken A (1986) Multisteroid analysis after DST in depressed patients-A controlled study. J Affect Disord 10: 241-249
42. Holsboer F, von Bardeleben U, Wiedemann K, Müller OA, Stalla GK (1987) Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatr 22: 228-234
43. Holsboer-Trachsler E, Stohler R, Hatzinger M (1991) Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatr Res 38: 163-171
44. Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113: 211-220
45. Ising M, Künzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005) The combined dexamethasone/ CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatr 29: 1085-1093
46. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, Künzel HE, Pfennig A, Uhr M, Holsboer F (2007) Combined Dexamethasone/Corticotropin Releasing Hormone test predicts treatment response in major depression-A potential biomarker? Biol Psychiatr 62: 47-54
47. Jackson IM (1998) The thyroid axis and depression. Thyroid 8: 951-956
48. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Müller N, Lieb R (2004) Prevalence, comorbidity and correlates of mental disorders in the general population: Results from the German Health Interview and Examination Survey (GHS). Psychol Med 34: 597-611
49. Kartha A, Anthony D, Manasseh CS, Greenwald JL, Chetty VK, Burgess JF, Culpepper L, Jack BW (2007) Depression Is a Risk Factor for Rehospitalization in Medical Inpatients. Prim Care Companion J Clin Psychiatr 9: 256-262
50. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatr 51: 8-19
51. Kimura M, Steiger A (2008) Sleep EEG provides biomarker in depression. In: Turck CW (ed) Biomarkers for psychiatric disorders. Springer, Berlin Heidelberg New York
52. Kromer SA, Kessler MS, Milfay D, Birg IN, Bunck M, Czibere L, P anhuysen M, Putz B, Deussing JM, Holsboer F, Landgraf R, Turck CW (2005) Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25: 4375-4384
53. Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, Yabana T, Urushibara T, Kanai R, Aihara M, Yuuki N, Otsubo T, Oshima A, Kudo K, Inoue T, Kitaichi Y, Shirakawa O, Isogawa K, Nagayama H, Kamijima K, Nanko S, Kanba S, Higuchi T, Mikuni M (2006) Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitaryadrenal (HPA) axis abnormalities in major depressive episode: A Multicenter Study. Neuropsychopharmacology 31: 212-220
54. Kupfer DJ, Foster FG, Reich L, Thompson SK, Weiss B (1976) EEG sleep changes as predictors in depression. Am J Psychiatr 133: 622-626
55. Kupfer DJ, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH (1980) Depression, EEG sleep, and clinical response. Compr Psychiatr 21: 212-220
56. Lal S (1988) Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatr 12: 117-164
57. Leuchter AF, Cook IA, Lufkin RB, Dunkin J, Newton TF, Cummings JL, Mackey JK, Walter DO (1994) Cordance: A new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1: 208-219
58. McPherson H, Walsh A, Silverstone T (2003) Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord 76: 121-125
59. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H (2004) Dysregulation in the suicide brain: MRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24: 1478-1485
60. Modrego PJ, Ferrandez J (2004) Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: A prospective cohort study. Arch Neurol 61: 1290-1293
61. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, E klund K, K ilts CD, Loosen PT, Vale WW (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344
62. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatr 45: 577-579
63. Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, Murck H, Ising M, Yassouridis A, Steiger A, Zihl J, Holsboer F (2003) Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 28: 155-168
64. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ (2007) Short-Term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br J Psychiatr 190: 531-532
65. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW (2004) Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29: 423-447
66. Pollock VE, Schneider LS (1990) Quantitative, waking EEG research on depression. Biol Psychiatr 27: 757-780
67. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60: 436-444
68. Raison CL, Miller AH (2003) When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatr 160: 1554-1565
69. Reul JM, Stec I, Soeder M, Holsboer F (1993) Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-Adrenocortical system. Endocrinology 133: 312-320
70. Ribeiro SC, Tandon R, Grunhaus L, Greden JF (1993) The DST as a predictor of outcome in depression: A meta-Analysis. Am J Psychiatr 150: 1618-1629
71. Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, van den Brink W (2003) Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology 28: 126-132
72. Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E (1993) Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment. Am J Psychiatr 150: 1164-1168
73. Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW (1987) CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatr 144: 641-645
74. Rubin RT, Poland RE, Lesser IM, Winston RA, Blodgett ALN (1987) Neuroendocrine aspects of primary endogenous depression. Arch Gen Psychiatr 44: 336
75. Rybakowski JK, Twardowska K (1999) The dexamethasone/corticotropin- releasing hormone test in depression in bipolar and unipolar affective illness. Journal of Psychiatr Res 33: 363-370
76. Sachar EJ (1967) Corticosteroids in depressive illness II A longitudinal psychoendocrine study. Arch Gen Psychiatr 17: 554-567
77. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC (1996) Dysregulation of the hypothalamic-pituitary-Adrenocortical system in panic disorder. Neuropsychopharmacology 15: 7-15
78. Schüle C, Baghai T, Zwanzger P, Ella R, Eser D, Padberg F, Möller HJ, Rupprecht R (2003) Attenuation of hypothalamic-pituitary- Adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology 166: 271-275
79. Sharpley AL, Cowen PJ (1995) Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatr 37: 85-98
80. Steiger A (2007) Neuroendocrinology of Sleep. In: Lajtha A, Blaustein J (eds) Handbook of Neurochemestry and Molecular Neurobiology-Behavioral Neurochemistry, Neuroendocrinology and Molecular Neurobiology. Springer, Berlin Heidelberg New York, pp 897-932
81. Tancer ME, Stein MB, Uhde TW (1993) Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers. Biol Psychiatr 34: 591-595
82. Thase ME, Kupfer DJ, Fasiczka AJ, Buysse DJ, Simons AD, Frank E (1997) Identifying an abnormal electroencephalographic sleep profile to characterize major depressive disorder. Biol Psychiatr 41: 964-973
83. Tsuno N, Besset A, Ritchie K (2005) Sleep and depression. J Clin Psychiatr 66: 1254-1269
84. Tukel R, Kora K, Hekim N, Oguz H, Alagol F (1999) Thyrotropin stimulating hormone response to thyrotropin releasing hormone in patients with panic disorder. Psychoneuroendocrinology 24: 155-160
85. Turck CW, Ditzen C, Sayan-Ayata EF (2008) Proteomic strategies for biomarker discovery: From differential expression to isoforms to pathways. In: Turck CW (ed) Biomarkers for psychiatric disorders. Springer, Berlin Heidelberg New York
86. Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, Mellman TA (1989) Behavioral and physiologic effects of short-Term and long-Term administration of clonidine in panic disorder. Arch Gen Psychiatr 46: 170-177
87. Valdivieso S, Duval F, Mokrani MC, Schaltenbrand N, Castro JO, Crocq MA, Macher JP (1996) Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients. Psychiatr Res 60: 23-32
88. Watson S, Gallagher P, Del-Estal D, H earn A, F errier I N, Y oung A H ( 2002) H ypothalamic-pituitary-Adrenal axis function in patients with chronic depression. Psychol Med 32: 1021-1028
89. WHO European Ministerial Conference (2005) Mental health: Fac-ing the challenges, building solutions. WHO Regional Office for Europe, Copenhagen
90. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999) Prediction of medium-Term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatr 156: 949-951
91. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 35: 83-94